

**AMETEK, Inc.**  
**Reconciliations of Non-GAAP Financial Measures (Unaudited)**

**EBITDA**

EBITDA represents earnings before interest, income taxes, depreciation and amortization. EBITDA is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. It should not be considered, however, as an alternative to operating income as an indicator of the Company's operating performance or as an alternative to cash flows as a measure of the Company's overall liquidity as presented in the Company's consolidated financial statements. The table below presents the reconciliation of net income reported in accordance with U.S. GAAP to EBITDA.

(In millions)	Three Months Ended	Six Months Ended	Year Ended December 31,		
	June 30, 2018	June 30, 2018	2017	2016	2015
Net income.....	\$ 193.9	\$ 375.2	\$ 681.5	\$ 512.2	\$ 590.9
Add (deduct):					
Interest expense.....	20.8	42.5	98.0	94.3	91.8
Interest income.....	(0.4)	(0.7)	(2.0)	(1.1)	(0.8)
Income taxes.....	54.4	108.8	115.3	180.9	215.5
Depreciation.....	20.8	42.0	82.0	74.8	68.7
Amortization.....	28.1	55.8	101.2	104.9	80.8
EBITDA.....	<u>\$ 317.6</u>	<u>\$ 623.6</u>	<u>\$ 1,076.0</u>	<u>\$ 966.0</u>	<u>\$ 1,046.9</u>

**FREE CASH FLOW**

Free cash flow represents cash flow from operating activities less capital expenditures. Free cash flow is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. (Also see EBITDA headnote above). The table below presents the reconciliation of cash flow from operating activities reported in accordance with U.S. GAAP to free cash flow.

(In millions)	Three Months Ended	Six Months Ended	Year Ended December 31,		
	June 30, 2018	June 30, 2018	2017	2016	2015
Cash provided by operating activities.....	\$ 203.1	\$ 380.5	\$ 833.3	\$ 756.8	\$ 672.5
Deduct: Capital expenditures.....	(16.3)	(28.6)	(75.1)	(63.3)	(69.1)
Free cash flow.....	<u>186.8</u>	<u>351.9</u>	<u>758.2</u>	<u>693.5</u>	<u>603.4</u>
Add: Special defined benefit pension plans contributions.....	-	-	50.1	-	50.0
Adjusted free cash flow.....	<u>\$ 186.8</u>	<u>\$ 351.9</u>	<u>\$ 808.3</u>	<u>\$ 693.5</u>	<u>\$ 653.4</u>

**NET DEBT AS A PERCENTAGE OF CAPITALIZATION**

Net debt represents total debt, net minus cash and cash equivalents. Net debt is presented because the Company is aware that it is used by rating agencies, securities analysts, investors and other parties in evaluating the Company. (Also see EBITDA headnote above). The table below presents the reconciliation of total debt, net reported in accordance with U.S. GAAP to net debt.

(In millions)	June 30, 2018	December 31,		
		2017	2016	2015
Total debt, net.....	\$ 2,145.9	\$ 2,174.3	\$ 2,341.6	\$ 1,938.0
Less: Cash and cash equivalents.....	(557.7)	(646.3)	(717.3)	(381.0)
Net debt.....	<u>1,588.2</u>	<u>1,528.0</u>	<u>1,624.3</u>	<u>1,557.0</u>
Stockholders' equity.....	4,338.1	4,027.6	3,256.5	3,254.6
Capitalization (net debt plus stockholders' equity).....	<u>\$ 5,926.3</u>	<u>\$ 5,555.6</u>	<u>\$ 4,880.8</u>	<u>\$ 4,811.6</u>
Net debt as a percentage of capitalization.....	<u>26.8%</u>	<u>27.5%</u>	<u>33.3%</u>	<u>32.4%</u>

Amounts as issued on February 1, 2018. Amounts do not include the subsequent retrospective adoption of ASU 2017-07. For 2017 impact of ASU 2017-07 adoption, see "Pension Accounting Change Reconciliation" for more details.

**AMETEK, Inc.**  
**Reconciliations of GAAP to Non-GAAP Financial Measures**  
(In thousands, except per share amounts)  
(Unaudited)

	Year Ended December 31,	
	2017	2016
EIG Segment operating income (GAAP)	\$ 677,489	\$ 577,717
Realignment costs	4,534	12,355
Indefinite-lived intangibles impairment	-	9,200
Adjusted EIG Segment operating income (Non-GAAP)	<u>\$ 682,023</u>	<u>\$ 599,272</u>
EMG Segment operating income (GAAP)	\$ 310,875	\$ 277,873
Realignment costs	12,252	11,644
Indefinite-lived intangibles impairment	-	4,700
Adjusted EMG Segment operating income (Non-GAAP)	<u>\$ 323,127</u>	<u>\$ 294,217</u>
Selling, general and administrative (GAAP)	\$ 533,645	\$ 462,970
Realignment costs	-	1,557
Charitable donations	5,000	-
Adjusted selling, general and administrative (Non-GAAP)	<u>\$ 528,645</u>	<u>\$ 461,413</u>
Operating income (GAAP)	\$ 915,094	\$ 801,897
Realignment costs	16,786	25,556
Charitable donations	5,000	-
Indefinite-lived intangibles impairment	-	13,900
Adjusted Operating income (Non-GAAP)	<u>\$ 936,880</u>	<u>\$ 841,353</u>
Provision for income taxes (GAAP)	\$ 115,259	\$ 180,945
Income tax benefit on realignment costs	3,821	8,578
Income tax benefit on charitable donations	1,885	-
Net deferred tax revaluation due to Tax Reform <sup>(1)</sup>	185,781	-
Deemed repatriation of foreign earnings due to Tax Reform <sup>(1)</sup>	(94,191)	-
Income tax benefit on indefinite-lived intangibles impairment	-	5,310
Adjusted provision for income taxes (Non-GAAP)	<u>\$ 212,555</u>	<u>\$ 194,833</u>
Net income (GAAP)	\$ 681,470	\$ 512,158
Realignment costs	12,965	16,978
Charitable donations	3,115	-
Net deferred tax revaluation due to Tax Reform <sup>(1)</sup>	(185,781)	-
Deemed repatriation of foreign earnings due to Tax Reform <sup>(1)</sup>	94,191	-
Indefinite-lived intangibles impairment	-	8,590
Adjusted Net income (Non-GAAP)	<u>\$ 605,960</u>	<u>\$ 537,726</u>
Diluted earnings per share (GAAP)	\$ 2.94	\$ 2.19
Realignment costs	0.07	0.11
Income tax benefit on realignment costs	(0.02)	(0.04)
Charitable donations	0.02	-
Income tax benefit on charitable donations	(0.01)	-
Net deferred tax revaluation due to Tax Reform <sup>(1)</sup>	(0.80)	-
Deemed repatriation of foreign earnings due to Tax Reform <sup>(1)</sup>	0.41	-
Indefinite-lived intangibles impairment	-	0.06
Income tax benefit on indefinite-lived intangibles impairment	-	(0.02)
Adjusted Diluted earnings per share (Non-GAAP)	<u>\$ 2.61</u>	<u>\$ 2.30</u>
EIG Segment operating margin (GAAP)	25.2%	24.5%
Realignment costs	0.1	0.5
Indefinite-lived intangibles impairment	-	0.4
Adjusted EIG Segment operating margin (Non-GAAP)	<u>25.3%</u>	<u>25.4%</u>
EMG Segment operating margin (GAAP)	19.3%	18.8%
Realignment costs	0.8	0.8
Indefinite-lived intangibles impairment	-	0.3
Adjusted EMG Segment operating margin (Non-GAAP)	<u>20.1%</u>	<u>19.9%</u>

Amounts as issued on February 1, 2018. Amounts do not include the subsequent retrospective adoption of ASU 2017-07. For 2017 impact of ASU 2017-07 adoption, see “Pension Accounting Change Reconciliation” for more details.

**AMETEK, Inc.**  
**Reconciliations of GAAP to Non-GAAP Financial Measures**  
(In thousands, except per share amounts)  
(Unaudited)

	Year Ended December 31,	
	2017	2016
Operating income margin (GAAP)	21.3%	20.9%
Realignment costs	0.4	0.7
Charitable donations	0.1	-
Indefinite-lived intangibles impairment	-	0.3
Adjusted Operating income margin (Non-GAAP)	<u>21.8%</u>	<u>21.9%</u>
Effective tax rate (GAAP)	14.5%	26.1%
Realignment costs	(0.1)	0.3
Charitable donations	0.1	-
Net deferred tax revaluation due to Tax Reform <sup>(1)</sup>	23.3	-
Deemed repatriation of foreign earnings due to Tax Reform <sup>(1)</sup>	(11.8)	-
Indefinite-lived intangibles impairment	-	0.2
Adjusted Effective tax rate (Non-GAAP)	<u>26.0%</u>	<u>26.6%</u>

(1) - These amounts, which are based on reasonable estimates, will require further adjustments as additional guidance from the U.S. Department of Treasury is provided, the Company's assumptions change, or as further information and interpretations become available.

**Use of Non-GAAP Financial Information**

The Company supplements its consolidated financial statements presented on a U.S. generally accepted accounting principles (“GAAP”) basis with certain non-GAAP financial information to provide investors with greater insight, increased transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Reconciliation of non-GAAP measures to their most directly comparable GAAP measures are included in the accompanying financial tables. These non-GAAP financial measures should be considered in addition to, and not as a replacement for, or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.

The Company believes that these measures provide useful information to investors by reflecting additional ways of viewing AMETEK’s operations that, when reconciled to the comparable GAAP measure, helps our investors to better understand the long-term profitability trends of our business, and facilitates easier comparisons of our profitability to prior and future periods and to our peers. The items described above have been excluded from this measure because items of this nature and/or size occur with inconsistent frequency, occur for reasons that may be unrelated to AMETEK’s commercial performance during the period and/or we believe are not indicative of AMETEK’s ongoing operating costs or gains in a given period, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.

Amounts as issued on February 1, 2018. Amounts do not include the subsequent retrospective adoption of ASU 2017-07. For 2017 impact of ASU 2017-07 adoption, see "Pension Accounting Change Reconciliation" for more details.

**AMETEK, Inc.**  
**Reconciliations of GAAP to Non-GAAP Financial Measures**  
(In thousands, except per share amounts)  
(Unaudited)

	Year Ended December 31,		
	2016	2015	2014
EIG Segment operating income (GAAP)	\$ 577,717	\$ 639,399	\$ 612,992
Realignment costs	12,355	18,518	-
Indefinite-lived intangibles impairment	9,200	-	-
Zygo integration costs	-	-	18,877
Adjusted EIG Segment operating income (Non-GAAP)	<u>\$ 599,272</u>	<u>\$ 657,917</u>	<u>\$ 631,869</u>
EMG Segment operating income (GAAP)	\$ 277,873	\$ 318,098	\$ 335,046
Realignment costs	11,644	17,298	-
Indefinite-lived intangibles impairment	4,700	-	-
Adjusted EMG Segment operating income (Non-GAAP)	<u>\$ 294,217</u>	<u>\$ 335,396</u>	<u>\$ 335,046</u>
Operating income (GAAP)	\$ 801,897	\$ 907,716	\$ 898,586
Realignment costs	25,556	36,605	-
Indefinite-lived intangibles impairment	13,900	-	-
Zygo integration costs	-	-	18,877
Adjusted Operating income (Non-GAAP)	<u>\$ 841,353</u>	<u>\$ 944,321</u>	<u>\$ 917,463</u>
Net income (GAAP)	\$ 512,158	\$ 590,859	\$ 584,460
Realignment costs	25,556	36,605	-
Income tax benefit on realignment costs	(8,578)	(11,929)	-
Indefinite-lived intangibles impairment	13,900	-	-
Income tax benefit on indefinite-lived intangibles impairment	(5,310)	-	-
Zygo integration costs	-	-	18,877
Income tax benefit on Zygo integration costs	-	-	(4,983)
Adjusted Net income (Non-GAAP)	<u>\$ 537,726</u>	<u>\$ 615,535</u>	<u>\$ 598,354</u>
Diluted earnings per share (GAAP)	\$ 2.19	\$ 2.45	\$ 2.37
Realignment costs	0.11	0.15	-
Income tax benefit on realignment costs	(0.04)	(0.05)	-
Indefinite-lived intangibles impairment	0.06	-	-
Income tax benefit on indefinite-lived intangibles impairment	(0.02)	-	-
Zygo integration costs	-	-	0.08
Income tax benefit on Zygo integration costs	-	-	(0.03)
Adjusted Diluted earnings per share (Non-GAAP)	<u>\$ 2.30</u>	<u>\$ 2.55</u>	<u>\$ 2.42</u>
EIG Segment operating margin (GAAP)	24.5%	26.5%	25.3%
Realignment costs	0.5	0.7	-
Indefinite-lived intangibles impairment	0.4	-	-
Zygo integration costs	-	-	0.8
Adjusted EIG Segment operating margin (Non-GAAP)	<u>25.4%</u>	<u>27.2%</u>	<u>26.1%</u>
EMG Segment operating margin (GAAP)	18.8%	20.4%	20.9%
Realignment costs	0.8	1.1	-
Indefinite-lived intangibles impairment	0.3	-	-
Adjusted EMG Segment operating margin (Non-GAAP)	<u>19.9%</u>	<u>21.5%</u>	<u>20.9%</u>
Operating income margin (GAAP)	20.9%	22.8%	22.3%
Realignment costs	0.7	1.0	-
Indefinite-lived intangibles impairment	0.3	-	-
Zygo integration costs	-	-	0.5
Adjusted Operating income margin (Non-GAAP)	<u>21.9%</u>	<u>23.8%</u>	<u>22.8%</u>

**Use of Non-GAAP Financial Information**

The Company supplements its consolidated financial statements presented on a U.S. generally accepted accounting principles ("GAAP") basis with certain non-GAAP financial information to provide investors with greater insight, increased transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making. Reconciliation of non-GAAP measures to their most directly comparable GAAP measures are included in the accompanying financial tables. These non-GAAP financial measures should be considered in addition to, and not as a replacement for, or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.

The Company believes that these measures provide useful information to investors by reflecting additional ways of viewing AMETEK's operations that, when reconciled to the comparable GAAP measure, helps our investors to better understand the long-term profitability trends of our business, and facilitates easier comparisons of our profitability to prior and future periods and to our peers. The items described above have been excluded from this measure because items of this nature and/or size occur with inconsistent frequency, occur for reasons that may be unrelated to AMETEK's commercial performance during the period and/or we believe are not indicative of AMETEK's ongoing operating costs or gains in a given period, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.